Science News
from research organizations

T-cell therapy clinical trial now offered to cancer patients in Michigan

Date:
February 23, 2015
Source:
University of Michigan Health System
Summary:
A clinical trial using T-cell therapy that uses the patients' own immune cells to hunt down cancer cells is now being offered at the University of Michigan's C.S. Mott Children's Hospital.
Share:
FULL STORY

A clinical trial using T-cell therapy that uses the patients' own immune cells to hunt down cancer cells is now being offered at the University of Michigan's C.S. Mott Children's Hospital.

"For patients for whom we've exhausted all other options, this therapy has provided hope against a highly aggressive form of ALL, in situations where nothing else has been successful," says John Levine, M.D., clinical director of the Pediatric Blood and Marrow Transplantation Program at C.S. Mott Children's Hospital.

To begin the treatment process, researchers first extract a patient's own T cells. They then use bioengineering techniques to reprogram each patient's T cells into chimeric antigen receptor cells -- the CTL019 cells -- custom-designed to bind to a protein called CD19 that exists only on the surface of B cells. After being returned to the patient's body, the CTL019 cells proliferate and then hunt B cells that express CD19. They also may persist in the circulation, which may guard against the cancer's recurrence.

"We are very proud to play an active role in this exciting new research that can offer new breakthroughs and hope for our pediatric cancer patients," says Levine, a professor of pediatrics in the University of Michigan Medical School.

In July 2014, the U.S. Food and Drug Administration designated CTL019 as a Breakthrough Therapy, helping to expedite its progress into broader clinical trials.

The trial opened in late October at Mott. Patients interested in participating should contact the center at 1-800-865-1125 to determine their eligibility.

Side effects from the treatment can include symptoms of cytokine release syndrome (CRS), which occurs when CAR cells and multiply in the patient's body resulting in the release of cytokines. CRS symptoms include varying degrees of flu-like symptoms with high fevers, nausea, muscle pain, and in some cases, low blood pressure and breathing difficulties.


Story Source:

Materials provided by University of Michigan Health System. Note: Content may be edited for style and length.


Cite This Page:

University of Michigan Health System. "T-cell therapy clinical trial now offered to cancer patients in Michigan." ScienceDaily. ScienceDaily, 23 February 2015. <www.sciencedaily.com/releases/2015/02/150223164205.htm>.
University of Michigan Health System. (2015, February 23). T-cell therapy clinical trial now offered to cancer patients in Michigan. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/02/150223164205.htm
University of Michigan Health System. "T-cell therapy clinical trial now offered to cancer patients in Michigan." ScienceDaily. www.sciencedaily.com/releases/2015/02/150223164205.htm (accessed May 23, 2017).

RELATED STORIES